Spironolactone description, usages, side effects, indications, overdosage, supplying and lots more!

Menu
Search

Spironolactone

REMEDYREPACK INC.


FULL PRESCRIBING INFORMATION: CONTENTS*




FULL PRESCRIBING INFORMATION

BOXED WARNING

WARNING
Spironolactone has been shown to be a tumorigen in chronic toxicity studies in rats (seePRECAUTIONS). Spironolactone should be used only in those conditions described underINDICATIONS AND USAGE. Unnecessary use of this drug should be avoided.


SPIRONOLACTONE DESCRIPTION


Spironolactone






CLINICAL PHARMACOLOGY

Mechanism of Action.


Aldosterone Antagonist Activity.





PHARMACOKINETICS







CLINICAL STUDIES

CLINICAL STUDIES

Severe Heart Failure.






Spironolactone





Spironolactone



INDICATIONS & USAGE



Primary hyperaldosteronism for:





Edematous conditions for patients with:




Essential hypertension


Hypokalemia


Severe heart failure (NYHA class III - IV)


Usage in Pregnancy.


PRECAUTIONS: Pregnancy
There is hypervolemia during normal pregnancy which is not harmful to either the fetus or the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate.

SPIRONOLACTONE CONTRAINDICATIONS



WARNINGS


Potassium Supplementation.

PRECAUTIONS: General

Hyperkalemia in Patients with Severe Heart Failure.
CLINICAL STUDIES, Severe Heart FailureDOSAGE AND ADMINISTRATION, Severe Heart Failure

PRECAUTIONS: Drug Interactions

PRECAUTIONS

General.










INFORMATION FOR PATIENTS



LABORATORY TESTS



DRUG INTERACTIONS

ACE Inhibitors:


Alcohol, Barbiturates, or Narcotics:


Corticosteroids, ACTH:


Pressor Amines (e.g., Norepinephrine):


Skeletal Muscle Relaxants, Nondepolarizing (e.g.,Tubocurarine):


Lithium:


Nonsteroidal Anti-Inflammatory Drugs (NSAIDs):


Digoxin:


DRUG & OR LABORATORY TEST INTERACTIONS



CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY






PREGNANCY

Teratogenic Effects.

Pregnancy Category C.


NURSING MOTHERS



PEDIATRIC USE



SPIRONOLACTONE ADVERSE REACTIONS



PRECAUTIONS


WARNINGSPRECAUTIONS




OVERDOSAGE




Treatment.



DOSAGE & ADMINISTRATION

Primary Hyperaldosteronism.





Edema in Adults (Congestive Heart Failure, Hepatic Cirrhosis, or Nephrotic Syndrome).


Essential Hypertension.


Hypokalemia.


Severe Heart Failure (NYHA class IIIIV).
WARNINGS: Hyperkalemia in Patients with Severe Heart Failure

HOW SUPPLIED









STORAGE AND HANDLING



PACKAGE LABEL.PRINCIPAL DISPLAY PANEL SECTION














Spironolactone

Spironolactone

Spironolactone TABLET

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:49349-563(NDC:0603-5763)
Route of Administration ORAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
SPIRONOLACTONE SPIRONOLACTONE 25 mg

Inactive Ingredients

Ingredient Name Strength
CALCIUM SULFATE
HYPROMELLOSES
MAGNESIUM STEARATE
cellulose, microcrystalline
polyethylene glycol
polysorbate 80
povidone
SODIUM STARCH GLYCOLATE TYPE A POTATO
talc
titanium dioxide

Product Characteristics

Color Size Imprint Code Shape
white 8 mm 5880;V ROUND

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:49349-563-28 300 in 1 CANISTER

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA040750 2011-10-07


PLEASE, BE CAREFUL!
Be sure to consult your doctor before taking any medication!
Copyright © 2014. drugs-library.com. All rights reserved. Information on drugs-library.com is provided for educational purposes only and is not to be used for medical advice, diagnosis or treatment.
Support info@drugs-library.com.